Synergy Pharmaceuticals Inc (SGYP.O)
11 Jul 2014
|Market Cap (Mil.):||$360.74|
|Shares Outstanding (Mil.):||93.70|
- Synergy Pharmaceuticals Inc said its constipation drug improved the frequency of complete spontaneous bowel movements in patients with a form of irritable bowel syndrome, reinforcing investor hopes that the data would boost chances of a buyout.
April 30 - Synergy Pharmaceuticals Inc said its constipation drug improved the frequency of complete spontaneous bowel movements in patients with a form of irritable bowel syndrome, reinforcing investor hopes that the data would boost chances of a buyout.
|Takeda Pharmaceutical Co Ltd (4502.T)||¥4,663||+8.00|
|Forest Laboratories, Inc. (FRX.N)||--||--|
|Shire PLC (SHP.L)||4,870.00p||+270.00|
|Shire PLC (3159084.L)||--||--|
|Salix Pharmaceuticals, Ltd. (SLXP.OQ)||$131.81||-2.03|
|Ironwood Pharmaceuticals, Inc. (IRWD.OQ)||$14.85||+0.44|
|Sucampo Pharmaceuticals, Inc. (SCMP.OQ)||$6.82||+0.03|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
"The Economy Matters" Report for SGYP: the economy's impact on SGYP's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Synergy Pharmaceuticals Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Ford Investor Services, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.